Author
Listed:
- Kevin Klein
(Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University
TI Pharma Escher
Exon Consultancy)
- Joep H. G. Scholl
(The Netherlands Pharmacovigilance Centre Lareb)
- Niels S. Vermeer
(Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University
Medicines Evaluation Board (MEB))
- André W. Broekmans
(TI Pharma Escher)
- Eugène P. Puijenbroek
(The Netherlands Pharmacovigilance Centre Lareb)
- Marie L. Bruin
(Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University
Medicines Evaluation Board (MEB))
- Pieter Stolk
(Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University
TI Pharma Escher
Exon Consultancy)
Abstract
Introduction and Objective Pharmacovigilance requirements for biologics mandate that EU Member States shall ensure that any biologic that is the subject of a suspected adverse drug reaction (ADR) is identifiable by brand name and batch number. Recent studies showed that brand name identification is well established, whereas batch numbers are (still) poorly reported. We evaluated information-recording systems and practices in the Dutch hospital setting to identify determinants for brand name and batch number recording as well as success factors and bottlenecks for traceability. Methods We surveyed Dutch hospital pharmacists with an online questionnaire on systems and practices in hospitals for recording brand names and batch numbers. Additionally, we performed an analysis of the traceability of recombinant biologics in spontaneous ADR reports (received between 2009 and 2014) from the Netherlands Pharmacovigilance Centre Lareb. Results The survey showed that brand names are not routinely recorded in the clinical practice of Dutch hospitals, whereas batch numbers are poorly recorded. Seventy-six percent of the 1523 ADR reports for recombinant biologics had a traceable brand name whereas 5 % of these reports contained a batch number. The results suggest a possible relationship between the availability of brand and batch number information in clinical practice and the inclusion of this information in ADR reports for biologics. Conclusion The limited traceability of brand names and batch numbers in ADR reports may be primarily caused by the shortcomings in the recording of information in clinical practice. We recommend efforts to improve information-recording systems as a first step to improve the traceability of biologics in ADR reporting.
Suggested Citation
Kevin Klein & Joep H. G. Scholl & Niels S. Vermeer & André W. Broekmans & Eugène P. Puijenbroek & Marie L. Bruin & Pieter Stolk, 2016.
"Traceability of Biologics in The Netherlands: An Analysis of Information-Recording Systems in Clinical Practice and Spontaneous ADR Reports,"
Drug Safety, Springer, vol. 39(2), pages 185-192, February.
Handle:
RePEc:spr:drugsa:v:39:y:2016:i:2:d:10.1007_s40264-015-0383-8
DOI: 10.1007/s40264-015-0383-8
Download full text from publisher
As the access to this document is restricted, you may want to search for a different version of it.
Citations
Citations are extracted by the
CitEc Project, subscribe to its
RSS feed for this item.
Cited by:
- Stella Stergiopoulos & Carrie A. Brown & Thomas Felix & Gustavo Grampp & Kenneth A. Getz, 2016.
"A Survey of Adverse Event Reporting Practices Among US Healthcare Professionals,"
Drug Safety, Springer, vol. 39(11), pages 1117-1127, November.
- Ylenia Ingrasciotta & Paola M. Cutroneo & Ilaria Marcianò & Thijs Giezen & Fabiola Atzeni & Gianluca Trifirò, 2018.
"Safety of Biologics, Including Biosimilars: Perspectives on Current Status and Future Direction,"
Drug Safety, Springer, vol. 41(11), pages 1013-1022, November.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:drugsa:v:39:y:2016:i:2:d:10.1007_s40264-015-0383-8. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com/economics/journal/40264 .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.